Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Lorus Therapeutics announces final phase I/II pancreatic cancer trial data

Dec. 11, 1998

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Dec. 10, 1998

MGI Pharma expands prostate cancer study with MGI-114

Dec. 10, 1998

Techniclone initiates phase II trial for treatment of malignant glioma

Dec. 9, 1998

CMA-676 shows efficacy and excellent tolerability in patients with AML

Dec. 9, 1998

Excellent results obtained in AML patients receiving Maxamine plus IL-2

Dec. 9, 1998

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Dec. 9, 1998

Biomira initiates pivotal phase III trial of Theratope vaccine

Dec. 7, 1998

Maxamine Therapy enters phase II trial for late-stage RCC

Dec. 4, 1998

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Dec. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...